Emerald Advisers’s Catalyst Pharmaceutical CPRX Stock Holding History

Emerald Advisers’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,175,958	Closed	-$6.24M	–	339
2019 Q3	$6.24M	Buy	+1,175,958	New	+$6.26M	0.29%	104
2018 Q2	–	Sell	-1,346,316	Closed	-$3.22M	–	255
2018 Q1	$3.22M	Sell	1,346,316 -25,580	-2%	-$85K	0.13%	121
2017 Q4	$5.36M	Buy	+1,371,896	New	+$4.53M	0.21%	115

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Emerald Advisers's CPRX Position: Q4 2019 in Review

Emerald Advisers sold out of Catalyst Pharmaceutical (CPRX) in Q4 2019, closing a stake of 1,175,958 shares — an estimated $6.24M sold.

Emerald Advisers first reported a position in CPRX in Q4 2017 and held it in 3 quarters. The position peaked at $6.24M in Q3 2019. 130 funds tracked by Wall St. Rank hold CPRX as of Q4 2019.

Emerald Advisers reported no remaining Catalyst Pharmaceutical position as of Q4 2019 after selling out during the quarter.
Emerald Advisers sold 1,175,958 Catalyst Pharmaceutical shares in Q4 2019, an estimated $6.24M.
Emerald Advisers first reported a position in Catalyst Pharmaceutical in Q4 2017 and held it in 3 quarters.
Emerald Advisers's Catalyst Pharmaceutical position peaked at $6.24M in Q3 2019.
130 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2019.

Based on Emerald Advisers's 13F filing for Q4 2019, filed 29 Jan 2020.